2020 mTNBC trial drug handler.Interesting trail.....
From the 2020 mTNBC, 130 page Protocol:
6.1.1. Leronlimab (PRO 140) - Packaging and Labeling
Study drug will be prepared by Ajinomoto Althea, Inc. and will be packaged, labeled, and shipped by PCI Pharma Services.
___
Ajinomoto Althea, Inc 2023 news:
Kohlberg & Company now owns Ajinomoto Althea, Inc.
___
As of July 2025, PCI Pharma Services is primarily owned by a consortium led by Bain Capital and Kohlberg & Company, with significant reinvestment from the Mubadala Investment Company.
___
Kohlberg is also majority holder of Worldwide Clinical Trials --- a CRO.
"Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans nearly 60 countries with more than 3,300 team members."
___
Kohlberg is a leading U.S. middle market private equity firm based in Mount Kisco, New York. Over the firm’s 36-year history, the firm has organized 11 private equity vehicles totaling in aggregate over $14 billion. Since inception, the firm’s private equity investments have generated over $10 billion in realized returns with no realized losses since Fund VI (2007 vintage).
___
Just brainstorming started @ double back on mTNBC handling companies.
Looking @ maybe potential future funding source, if a bigger Cytodyn as solo, comes into view
___
When I only put the two companies names in a regular Google search:
Bain Capital and Kohlberg & Company are co-leading a multibillion-dollar strategic investment in PCI Pharma Services, valuing the global contract development and manufacturing organization (CDMO) at approximately $10 billion, including debt.
This partnership marks a new growth phase for PCI, with Kohlberg, a previous majority owner, reinvesting alongside Bain Capital.
WSJ
+4
Key Details of the Investment
Target Company: PCI Pharma Services, a Philadelphia-based company specializing in sterile fill-finish, clinical trial support, and packaging for pharma/biotech, including GLP-1 weight-loss drugs.
Deal Structure: Bain Capital and Kohlberg & Co. are lead investors, with support from existing stakeholders Mubadala Investment Company and Partners Group.
Growth Impact: Under previous ownership, PCI expanded its workforce to nearly 8,000 and doubled revenue.
The new investment will fund further international expansion and acquisitions.
Context: This deal highlights intense investor interest in the pharmaceutical supply chain and outsourcing sector.
Kohlberg
+4
Kohlberg & Company, founded in 1987 and based in Mount Kisco, NY, focuses on middle-market investments in healthcare and services.
Bain Capital, founded in 1984 in Boston, is a global investment firm with extensive holdings across various sectors, including healthcare and life sciences.
The Healthcare Investor
____
& the Mubadala Investment Company ----
Mubadala Investment Company — a sovereign investor — manages a diverse portfolio of assets and investments in the United Arab Emirates and abroad, to generate sustainable financial returns for its shareholder, the Government of Abu Dhabi.
Mubadala is investing and partnering at the leading edge of global growth and innovation to create opportunities for future generations. We will continue to support our leadership’s vision, as we build upon the legacy of the late Sheikh Zayed bin Sultan Al Nahyan, who envisioned a free, stable and dignified life for the people of this country.
Today, in line with HH Sheikh Zayed bin Sultan Al Nahyan’s vision, Mubadala is a USD 330 billion (AED 1,212 billion) business that spans six continents with interests across multiple sectors and asset classes. Headquartered in Abu Dhabi, Mubadala also has offices in London, Moscow, New York and Beijing.
https://www.mubadala.com/en/who-we-are/about-mubadala
___
I think Cytodyn can "find" funding to take Leronlimab as far as we choose too...
From the 2020 mTNBC, 130 page Protocol:
6.1.1. Leronlimab (PRO 140) - Packaging and Labeling
Study drug will be prepared by Ajinomoto Althea, Inc. and will be packaged, labeled, and shipped by PCI Pharma Services.
___
Ajinomoto Althea, Inc 2023 news:
Kohlberg & Company now owns Ajinomoto Althea, Inc.
___
As of July 2025, PCI Pharma Services is primarily owned by a consortium led by Bain Capital and Kohlberg & Company, with significant reinvestment from the Mubadala Investment Company.
___
Kohlberg is also majority holder of Worldwide Clinical Trials --- a CRO.
"Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans nearly 60 countries with more than 3,300 team members."
___
Kohlberg is a leading U.S. middle market private equity firm based in Mount Kisco, New York. Over the firm’s 36-year history, the firm has organized 11 private equity vehicles totaling in aggregate over $14 billion. Since inception, the firm’s private equity investments have generated over $10 billion in realized returns with no realized losses since Fund VI (2007 vintage).
___
Just brainstorming started @ double back on mTNBC handling companies.
Looking @ maybe potential future funding source, if a bigger Cytodyn as solo, comes into view
___
When I only put the two companies names in a regular Google search:
Bain Capital and Kohlberg & Company are co-leading a multibillion-dollar strategic investment in PCI Pharma Services, valuing the global contract development and manufacturing organization (CDMO) at approximately $10 billion, including debt.
This partnership marks a new growth phase for PCI, with Kohlberg, a previous majority owner, reinvesting alongside Bain Capital.
WSJ
+4
Key Details of the Investment
Target Company: PCI Pharma Services, a Philadelphia-based company specializing in sterile fill-finish, clinical trial support, and packaging for pharma/biotech, including GLP-1 weight-loss drugs.
Deal Structure: Bain Capital and Kohlberg & Co. are lead investors, with support from existing stakeholders Mubadala Investment Company and Partners Group.
Growth Impact: Under previous ownership, PCI expanded its workforce to nearly 8,000 and doubled revenue.
The new investment will fund further international expansion and acquisitions.
Context: This deal highlights intense investor interest in the pharmaceutical supply chain and outsourcing sector.
Kohlberg
+4
Kohlberg & Company, founded in 1987 and based in Mount Kisco, NY, focuses on middle-market investments in healthcare and services.
Bain Capital, founded in 1984 in Boston, is a global investment firm with extensive holdings across various sectors, including healthcare and life sciences.
The Healthcare Investor
____
& the Mubadala Investment Company ----
Mubadala Investment Company — a sovereign investor — manages a diverse portfolio of assets and investments in the United Arab Emirates and abroad, to generate sustainable financial returns for its shareholder, the Government of Abu Dhabi.
Mubadala is investing and partnering at the leading edge of global growth and innovation to create opportunities for future generations. We will continue to support our leadership’s vision, as we build upon the legacy of the late Sheikh Zayed bin Sultan Al Nahyan, who envisioned a free, stable and dignified life for the people of this country.
Today, in line with HH Sheikh Zayed bin Sultan Al Nahyan’s vision, Mubadala is a USD 330 billion (AED 1,212 billion) business that spans six continents with interests across multiple sectors and asset classes. Headquartered in Abu Dhabi, Mubadala also has offices in London, Moscow, New York and Beijing.
https://www.mubadala.com/en/who-we-are/about-mubadala
___
I think Cytodyn can "find" funding to take Leronlimab as far as we choose too...
4
